NCT07357285 Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO)
| NCT ID | NCT07357285 |
| Status | Recruiting |
| Phase | — |
| Sponsor | iVascular S.L.U. |
| Condition | Acute Ischemic Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 57 participants |
| Start Date | 2025-11-27 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 57 participants in total. It began in 2025-11-27 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the iNstroke 4F Thromboaspiration Catheter in Patients with Acute Ischaemic Stroke due to Primary Distal Medium Vessel Occlusions.
Eligibility Criteria
Inclusion Criteria: * Subjects aged ≥ 18 years. * Subjects with symptom onset up to 24 hours. * Isolated primary demonstrated occlusion in a distal medium vessel (Non-dominant or distal M2-MCA segment, M3 or M4 segments of MCA, A2-A3 segments of ACA, P1, P2 and P3 segments of PCA) identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA). * Baseline NIHSS score ≥5 assessed before the procedure. * Pre-stroke mRS score ≤ 2. * Subjects with an ASPECTS score ≥ 6. * Informed consent obtained in accordance with the applicable country-specific regulations and as approved by the Ethics Committee (EC). Exclusion Criteria: * Subjects aged \< 18. * Suspected secondary DMVO. Suspicion or evidence of primary LVO whether it has been treated or not with fibrinolytic therapy or mechanical thrombectomy that subsequently develops a DMVO. * Baseline NIHSS score \<5 assessed before the procedure. * Pre-stroke mRS score \>2. * Subjects with an ASPECTS score \<6. * Severe comorbidity and/or shortened life expectancy that will likely prevent improvement or follow up or that will render the procedure unlikely to benefit the patient. * Severe allergy to contrast media. * Subjects with intracranial atherosclerotic occlusive disease or extra- or intracranial dissection. * Medical history of thrombocytopenia (Platelets \<100,000). * Subjects with tandem occlusions (evidence of complete occlusion, high-grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery). * Subjects with occlusions in multiple vessels (e.g., MCA-M3 and ACA-A2), whether or not they undergo mechanical thrombectomy. * Subjects with cancer (with or without metastases) who have a life expectancy of less than 6 months. * Subjects participating in a clinical trial at the moment of the inclusion. * Subjects with pre-existing neurological or psychiatric illness that could confound the neurological or functional assessments.
Frequently Asked Questions
Who can join the NCT07357285 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07357285 currently recruiting?
Yes, NCT07357285 is actively recruiting participants. Visit ClinicalTrials.gov or contact iVascular S.L.U. to inquire about joining.
Where is the NCT07357285 trial being conducted?
This trial is being conducted at Bonn, Germany, Kiel, Germany, Marburg, Germany, Nuremberg, Germany and 7 additional locations.
Who is sponsoring the NCT07357285 clinical trial?
NCT07357285 is sponsored by iVascular S.L.U.. The trial plans to enroll 57 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.